¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

Á¦59Â÷ ´ëÇѺñ¸¸ÇÐȸ Ãá°èÇмú´ëȸ : 2024-03-09

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 

Á¦59Â÷ ´ëÇѺñ¸¸ÇÐȸ Ãá°èÇмú´ëȸ : 2024-03-09
±³À°ÀÏÀÚ : 2024-03-09
±³À°Àå¼Ò : ±×·£µå ¿öÄ¿Èú ¼­¿ï, ºñ½ºÅ¸È¦

±³À°ÁÖÁ¦ : Á¦59Â÷ ´ëÇѺñ¸¸ÇÐȸ Ãá°èÇмú´ëȸ

ÁÖÃÖ±â°ü : ´ëÇѺñ¸¸ÇÐȸ
´ã´çÀÚ : ÃÖÀ±Áö
¿¬¶ôó : 02-6941-0878  

À̸ÞÀÏ : obmichelin@kosso.or.kr

±³À°Á¾·ù : ³»°ú, ¿Ü°ú, ¼Ò¾Æû¼Ò³â°ú, °¡Á¤ÀÇÇаú

Âü¼®¿¹»óÀÎ : 800¸í
Èñ¸ÁÆòÁ¡ : 6Á¡

Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 27 ½Ã°£ 0ºÐ

¼¼ºÎ¼ö°­·á : 100,000¿ø  

ºñ°í "»çÀüµî·Ï: 30000¿ø/50000¿ø/60000¿ø/80000¿ø

ÇöÀåµî·Ï: 50000¿ø/70000¿ø/80000¿ø/100000¿ø 

Çлý: 30000¿ø *ÇлýÁõÁöÂüÇʼö" 


±¸ºÐ ¿ùÀÏ °­ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ

±³À°½Ã°£ 03¿ù 09ÀÏ VISTA 1 07:30~08:20 Cutting edge care of pitavastatin with ezetimibe combination therapy ±è°æ¼ö(ºÐ´çÂ÷º´¿ø)

±³À°½Ã°£ 03¿ù 09ÀÏ VISTA 1 08:30~08:55 Novel (non-approved) incretin-based therapies under investigation ¼ÕÀå¿ø(°¡Å縯ÀÇ´ë)

±³À°½Ã°£ 03¿ù 09ÀÏ VISTA 1 08:55~09:20 The Long and Winding Road: How long does it maintain the pharmacotherapy? ±èÁøÈ­(Á¶¼±ÀÇ´ë)

±³À°½Ã°£ 03¿ù 09ÀÏ VISTA 1 09:20~09:45 The beneficial effect of SGLT2i and Phentermine-Topiramate FDC combination therapy È«ÁØÈ­(À»ÁöÀÇ´ë)

Åä·Ð 03¿ù 09ÀÏ VISTA 1 09:45~10:00 ÅäÀÇ ¹ÚÁ¤È¯°íÇýÁø(ÇѾçÀÇ´ë °æºÏÀÇ´ë)

ÈÞ½Ä 03¿ù 09ÀÏ VISTA 1 10:00~10:10 Break ( )

±³À°½Ã°£ 03¿ù 09ÀÏ VISTA 1 10:10~10:35 Circadian rhythms, sleep, and obesity ÀÌ´Ù¿µ(°í·ÁÀÇ´ë)

±³À°½Ã°£ 03¿ù 09ÀÏ VISTA 1 10:35~11:00 The impact of air pollution on metabolic diseases ±èÇöÁø(±¹¸³¾Ï¼¾ÅÍ)

±³À°½Ã°£ 03¿ù 09ÀÏ VISTA 1 11:00~11:25 Atypical antipsychotics and appetite regulation strategies ¼ÕÁ¾¿ì(KAIST)

Åä·Ð 03¿ù 09ÀÏ VISTA 1 11:25~11:40 ÅäÀÇ Á¶À±Á¤¹èÀçÇö(´ë±¸°¡Å縯ÀÇ´ë °í·ÁÀÇ´ë)

ÈÞ½Ä 03¿ù 09ÀÏ VISTA 1 11:40~12:00 Á¡½É½Ã°£ ( )

±³À°½Ã°£ 03¿ù 09ÀÏ VISTA 1 12:00~12:40 What¡¯s new in T2D? Dapa + Sita combination! Á¤Ã¢Èñ(¿ï»êÀÇ´ë)

±³À°½Ã°£ 03¿ù 09ÀÏ VISTA 1 12:40~13:20 Obesity and Insulin Resistance ÀÌ°ü¿ì(¾ÆÁÖÀÇ´ë)

±³À°½Ã°£ 03¿ù 09ÀÏ VISTA 1 13:20~13:50 Implication of Ectopic Fat in People with Relatively Low BMI ÀÓ¼ö(¼­¿ïÀÇ´ë)

ÈÞ½Ä 03¿ù 09ÀÏ VISTA 1 13:50~14:00 Break ( )

±³À°½Ã°£ 03¿ù 09ÀÏ VISTA 1 14:00~14:25 Efficacy and Safety of Once-Weekly Semaglutide Update ³²°¡Àº(°í·ÁÀÇ´ë)

±³À°½Ã°£ 03¿ù 09ÀÏ VISTA 1 14:25~14:50 Once-weekly Tirzepatide ¹èÀçÇö(°í·ÁÀÇ´ë)

±³À°½Ã°£ 03¿ù 09ÀÏ VISTA 1 14:50~15:15 Daily oral GLP-1 receptor agonists ³ëÀº(ÇѸ²ÀÇ´ë)

Åä·Ð 03¿ù 09ÀÏ VISTA 1 15:15~15:30 ÅäÀÇ À̽Âȯ ±èÈÖ½Â(°¡Å縯ÀÇ´ë Áß¾ÓÀÇ´ë)

ÈÞ½Ä 03¿ù 09ÀÏ VISTA 1 15:30~15:40 Break ( )

±³À°½Ã°£ 03¿ù 09ÀÏ VISTA 1 15:40~16:10 Serotonin and Metabolism ±è°æ°ï(°¡ÃµÀÇ´ë)

±³À°½Ã°£ 03¿ù 09ÀÏ VISTA 1 16:10~16:35 ºñ¸¸°ú ³­ÀÓ Á¤¼±È­(¾Ð±¸Á¤ µÎ¹ø°º½ »êºÎÀΰú)

±³À°½Ã°£ 03¿ù 09ÀÏ VISTA 1 16:35~17:00 Obesity and Polycystic Ovary Syndrome ±èÁøÁÖ(¼­¿ïÀÇ´ë)

±³À°½Ã°£ 03¿ù 09ÀÏ VISTA 1 17:00~17:25 ¼Ò¾Æºñ¸¸°ú ¼ºÁ¶¼÷Áõ, Á¶±â ºÎ½Å¼ºÀå¹ß»ý ¾ç¾Æ¶÷(¼º±Õ°üÀÇ´ë)

Åä·Ð 03¿ù 09ÀÏ VISTA 1 17:25~17:40 ÅäÀÇ ¿À¹üÁ¶ ÀÌ°æ¾Ö(¼­¿ïÀÇ´ë ÀüºÏÀÇ´ë)

±³À°½Ã°£ 03¿ù 09ÀÏ VISTA 2 07:30~08:20 Cutting edge care of pitavastatin with ezetimibe combination therapy ±è°æ¼ö(ºÐ´çÂ÷º´¿ø)

±³À°½Ã°£ 03¿ù 09ÀÏ VISTA 2 08:30~08:55 Reduction of SPARC protects mice against NLRP3 inflammasome activation and obesity À¯½ÂÁø(ÇѸ²ÀÇ´ë)

±³À°½Ã°£ 03¿ù 09ÀÏ VISTA 2 08:55~09:20 The N-degron pathway mediates lipophagy: The chemical modulation of lipophagy in obesity and NAFLD ¹ÚÁÖ¿ø(ÀÌÈ­¿©´ë)

±³À°½Ã°£ 03¿ù 09ÀÏ VISTA 2 09:20~09:45 HMBA ameliorates obesity by MYH9- and ACTG1-dependent regulation of hypothalamic neuropeptides ±èÀº°æ(DGIST)

Åä·Ð 03¿ù 09ÀÏ VISTA 2 09:45~10:00 ÅäÀÇ ¼Ûµµ°æ ±èÇü¼®(ÀÌÈ­¿©´ë Ãæ³²ÀÇ´ë)

ÈÞ½Ä 03¿ù 09ÀÏ VISTA 2 10:00~10:10 Break ( )

±³À°½Ã°£ 03¿ù 09ÀÏ VISTA 2 10:10~10:35 The Significance of Ascorbic Acid in Regulating Thermogenesis and Energy Metabolism À̺À±â(ºÎ°æ´ë)

±³À°½Ã°£ 03¿ù 09ÀÏ VISTA 2 10:35~11:00 ANK-Binding Kinase 1 Serves as a Key Regulator of Hepatocyte Fitness in MAFLD ÇãÁø¿µ(¼­°­´ë)

±³À°½Ã°£ 03¿ù 09ÀÏ VISTA 2 11:00~11:25 How diets regulate MASH Development. Casp2-S1P: The new hepatic lipid regulator ±èÁÖ¿¬(ÇѾç´ë)

Åä·Ð 03¿ù 09ÀÏ VISTA 2 11:25~11:40 ÅäÀÇ ÀÌÇö½Â ±è¹Î¼ö(Ãæ³²ÀÇ´ë KIST)

ÈÞ½Ä 03¿ù 09ÀÏ VISTA 2 11:40~12:00 Á¡½É½Ã°£ ( )

±³À°½Ã°£ 03¿ù 09ÀÏ VISTA 2 12:00~12:40 What¡¯s new in T2D? Dapa + Sita combination! Á¤Ã¢Èñ(¿ï»êÀÇ´ë)

±³À°½Ã°£ 03¿ù 09ÀÏ VISTA 2 12:40~13:20 Obesity and Insulin Resistance ÀÌ°ü¿ì(¾ÆÁÖÀÇ´ë)

±³À°½Ã°£ 03¿ù 09ÀÏ VISTA 2 13:20~13:50 Implication of Ectopic Fat in People with Relatively Low BMI ÀÓ¼ö(¼­¿ïÀÇ´ë)

ÈÞ½Ä 03¿ù 09ÀÏ VISTA 2 13:50~14:00 Break ( )

±³À°½Ã°£ 03¿ù 09ÀÏ VISTA 2 14:00~14:25 Hypertension and cardiovascular disease ±è°æÈñ(¼¼Á¾º´¿ø)

±³À°½Ã°£ 03¿ù 09ÀÏ VISTA 2 14:25~14:50 Type 2 diabetes ¹ÚÇü±Ô(¼øõÇâÀÇ´ë)

±³À°½Ã°£ 03¿ù 09ÀÏ VISTA 2 14:50~15:15 Weight loss and weight regain ±Ç¿µ±Ù(°í·ÁÀÇ´ë)

Åä·Ð 03¿ù 09ÀÏ VISTA 2 15:15~15:30 ÅäÀÇ À̼º¹è ÀÌ»óÀÏ(¼¼Á¾º´¿ø Ãæ³²ÀÇ´ë)

ÈÞ½Ä 03¿ù 09ÀÏ VISTA 2 15:30~15:40 Break ( )

±³À°½Ã°£ 03¿ù 09ÀÏ VISTA 2 15:40~16:10 The Keys to Successful Nutrition Therapy for Persons with Obesity or Overweight ±èÀº¹Ì(°­ºÏ»ï¼ºº´¿ø)

±³À°½Ã°£ 03¿ù 09ÀÏ VISTA 2 16:10~16:35 Clinical Studies Using Standardized Data on Obesity and Metabolic Diseases ¿¬µ¿°Ç(°æÈñÀÇ´ë)

±³À°½Ã°£ 03¿ù 09ÀÏ VISTA 2 16:35~17:00 Obesity Fact Sheet for 2023 Á¤¼ö¹Î(¼­¿ïÀÇ´ë)

±³À°½Ã°£ 03¿ù 09ÀÏ VISTA 2 17:00~17:25 Obesity research using data from the National Health Insurance Service ÀÌ»ó¿­(°æÈñÀÇ´ë)

Åä·Ð 03¿ù 09ÀÏ VISTA 2 17:25~17:40 ÅäÀÇ ±è¼±¿µ ¹®ÁØÈ£(°æÈñÀÇ´ë ¼­¿ïÀÇ´ë)

±³À°½Ã°£ 03¿ù 09ÀÏ VISTA 3 07:30~08:20 Cutting edge care of pitavastatin with ezetimibe combination therapy ±è°æ¼ö(ºÐ´çÂ÷º´¿ø)

±³À°½Ã°£ 03¿ù 09ÀÏ VISTA 3 08:30~08:55 Estimation of Ultra-processed Food Intake among Korean adults ¹Ú¼ÒÇö(ÇѸ²´ë)

±³À°½Ã°£ 03¿ù 09ÀÏ VISTA 3 08:55~09:20 Ultra-processed foods intakes and obesity ½ÉÁö¼±(¿¬¼¼´ë)

±³À°½Ã°£ 03¿ù 09ÀÏ VISTA 3 09:20~09:45 Ultra-processed foods intake and all-cause and cardiovascular mortality ÀÌ»ó¾Æ(°­¿ø´ë)

Åä·Ð 03¿ù 09ÀÏ VISTA 3 09:45~10:00 ÅäÀÇ ÀÓÇöÁ¤ ±ÇÀ¯Áø(°æÈñ´ë ¿¬¼¼ÀÇ´ë ¿ëÀμ¼ºê¶õ½º)

ÈÞ½Ä 03¿ù 09ÀÏ VISTA 3 10:00~10:10 Break ( )

±³À°½Ã°£ 03¿ù 09ÀÏ VISTA 3 10:10~10:35 Circadian rhythm, obesity, and intermittent fasting ±Ç¿Àºó(¼­¿ïÀÇ´ë)

±³À°½Ã°£ 03¿ù 09ÀÏ VISTA 3 10:35~11:00 Chrononutrition and Time-Restricted Eatings Effect on Metabolic Health ¼ÛÀ±ÁÖ(°¡Å縯´ë)

±³À°½Ã°£ 03¿ù 09ÀÏ VISTA 3 11:00~11:25 Time-Restricted Eating-Integrating the What with the When ÀÌ¿¬Èñ(¾ÆÁִ뺴¿ø)

Åä·Ð 03¿ù 09ÀÏ VISTA 3 11:25~11:40 ÅäÀÇ ±ÇÇõÅ ¼Û¼öÁø(¼­¿ïÀÇ´ë Çѳ²´ë)

ÈÞ½Ä 03¿ù 09ÀÏ VISTA 3 11:40~12:00 Á¡½É½Ã°£ ( )

±³À°½Ã°£ 03¿ù 09ÀÏ VISTA 3 12:00~12:40 What¡¯s new in T2D? Dapa + Sita combination! Á¤Ã¢Èñ(¿ï»êÀÇ´ë)

±³À°½Ã°£ 03¿ù 09ÀÏ VISTA 3 12:40~13:20 Obesity and Insulin Resistance ÀÌ°ü¿ì(¾ÆÁÖÀÇ´ë)

±³À°½Ã°£ 03¿ù 09ÀÏ VISTA 3 13:20~13:50 Implication of Ectopic Fat in People with Relatively Low BMI ÀÓ¼ö(¼­¿ïÀÇ´ë)

ÈÞ½Ä 03¿ù 09ÀÏ VISTA 3 13:50~14:00 Break ( )

±³À°½Ã°£ 03¿ù 09ÀÏ VISTA 3 14:00~14:25 From obesogenic womb to obese adolescents ±èÀçÇö(¼­¿ïÀÇ´ë)

±³À°½Ã°£ 03¿ù 09ÀÏ VISTA 3 14:25~14:50 Causal links between chemical exposures and obesity in childhood and adolescence ±è½ÅÇý(ÀÎÁ¦ÀÇ´ë)

±³À°½Ã°£ 03¿ù 09ÀÏ VISTA 3 14:50~15:15 Obesogenic environment: How can government policy make a healthy environment for pediatric obesity? Á¤¼ÒÁ¤(°Ç±¹ÀÇ´ë)

Åä·Ð 03¿ù 09ÀÏ VISTA 3 15:15~15:30 ÅäÀÇ È«¿ëÈñ ±èÁø¿í(¼øõÇâÀÇ´ë È÷Æ÷Å©¶óŸÀÇ¿ø)

ÈÞ½Ä 03¿ù 09ÀÏ VISTA 3 15:30~15:40 Break ( )

±³À°½Ã°£ 03¿ù 09ÀÏ VISTA 3 16:10~16:35 Potential restorative effects of exercise for peripheral skeletal neuropathy and bone loss in a high-fat diet-induced type II diabetes model À̽¿ë(ÀÎõ´ë)

±³À°½Ã°£ 03¿ù 09ÀÏ VISTA 3 16:35~17:00 Regular exercise can how effectively transform our cardiovascular and brain health? ÇϹμº(¼­¿ï½Ã¸³´ë)

±³À°½Ã°£ 03¿ù 09ÀÏ VISTA 3 17:00~17:25 Exploring In Vivo Metabolic Fluxes Behind Insulin Resistance: Therapeutic Role of Exercise and Essential Amino Acids ±èÀÏ¿µ(°¡ÃµÀÇ´ë)

Åä·Ð 03¿ù 09ÀÏ VISTA 3 17:25~17:40 ÅäÀÇ À̹Îö ¹®È¿¿­(Â÷ÀÇ´ë ¼­¿ï´ë)

 

ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" Á¦59Â÷ ´ëÇѺñ¸¸ÇÐȸ Ãá°èÇмú´ëȸ : 2024-03-09""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û 2024 Á¦9ȸ Á¶Ç÷¸ð¼¼Æ÷ÀÌ½Ä ¾ÆÄ«µ¥¹Ì : 2024-03-09
´ÙÀ½±Û 2024³â °¡Ãµ´ë±æº´¿ø ÀçÈ°ÀÇÇаú ½ÉÆ÷Áö¾ö : 2024-03-09
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
240 ¼­¿ï ´ëÇÑ´ëÀåÇ×¹®ÇÐȸ International Colorectal Research Summit 2018 : 2018-09-09 0 468 2018-07-28
239 ºÎ»ê µ¿¾Æ´ëÇб³ÀÇ·á¿ø Á¦ 1ȸ µ¿¾Æ´ëÇб³ Á¤Çü¿Ü°ú °³¿øÀÇ ¿¬¼ö°­Á : 2018-09-09 0 1,154 2018-07-28
238 ¼­¿ï ¼­¿ï´ëÇб³º´¿ø 2018 SNU Orthopaedic Update(III) Foot & Ankle : 2018-09-09 0 936 2018-07-28
237 ºÎ»ê ¼¼ºê¶õ½ºº´¿ø 70Â÷ fresh cadaver shoulder arthroscopy workshop : 2018-09-09 0 456 2018-07-28
236 ºÎ»ê ´ëÇѽÅÀåÇÐȸ ºÎ¿ï°æ Ç÷¾×Åõ¼® ½ÉÆ÷Áö¾ö : 2018-09-09 0 1,224 2018-07-28
235 °æ±â ºÐ´ç¼­¿ï´ëÇб³º´¿ø °íÀ§Çè »ê¸ð/½Å»ý¾ÆÀÇ Ã³Ä¡ ¹× °£È£ : 2018-09-09 0 461 2018-07-28
234 ¼­¿ï ¼¼ºê¶õ½ºº´¿ø ¼¼ºê¶õ½º ¾È°ú 133Áֳ⠱â³ä ½ÉÆ÷Áö¿ò : 2018-09-09 0 625 2018-07-28
233 °æ±â ¼øõÇâ´ëÇб³ºÎõº´¿ø ³»½Ã°æ ÃÊÀ½ÆÄ ¶óÀÌºê ½ÉÆ÷Áö¾ö 2018 : 2018-09-09 0 979 2018-07-28
232 ¼­¿ï 2018 ´ëÇѹ̿뼺Çü·¹ÀÌÀúÀÇÇÐȸ Ãß°èÇмú´ëȸ : 2018-09-09 0 3,294 2018-07-28
231 ¼­¿ï Á¦ 19ȸ ´ëÇÑÅõ¼®Çùȸ Ãß°è ½ÉÆ÷Áö¿ò : 2018-09-09 0 864 2018-07-28
230 ¼­¿ï ÀÌ´ë¸ñµ¿º´¿ø »êºÎÀΰú Áö¿ªÀÇ»ç °£´ãȸ : 2018-09-08 0 687 2018-07-28
229 Á¦ÁÖ ´ëÇÑ°áÇÙ¹×È£Èí±âÇÐȸ CAMP(Chronic Airway Management in Pulmonary disease) ½ÉÆ÷Áö¾ö : 2018-09-08 0 635 2018-07-28
228 ¼­¿ï 2018³âµµ ´ëÇѺñ¸¸ÇÐȸ ±¹Á¦Çмú´ëȸ(ICOMES 2018) - 09/08 : 2018-09-08 0 611 2018-07-28
227 ¼­¿ï 2018³â À»Áö´ëÇб³ À»Áöº´¿ø À̺ñÀÎÈÄ°ú °³¿øÀÇ ¿¬¼ö°­Á : 2018-09-08 0 1,203 2018-07-28
226 ¼­¿ï 2018³â ´ëÇѳëÀθ¶ÃëÅëÁõÇÐȸ Çмú´ëȸ : 2018-09-08 0 579 2018-07-28
1371 | 1372 | 1373 | 1374 | 1375 | 1376 | 1377 | 1378 | 1379 | 1380
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷